Skip to main content

Table 4 Progesterone immunoassay cross-reactivity

From: Cross-reactivity of steroid hormone immunoassays: clinical significance and two-dimensional molecular similarity prediction

Compound

Plasma/serum concentrations

Cross-reactivity in Roche assay

Likelihood of clinically significant cross-reactivity

Progesterone

• 0.2 – 1.4 ng/mL (males) [44]

100%

High (assay target)

• Up to 27 ng/mL (women) [44]

5β-Dihydroprogesterone

Up to 0.8 ng/mL in adults [45]

18.2%

Possible significant contribution for individuals with progesterone concentrations on the lower end of reference interval

17-Hydroxyprogesterone

• 0.08 – 2.0 ng/mL (pediatric controls) [22]

1.2%

Low, except in patients with 21-hydroxylase deficiency

• Up to 1,005 ng/mL (21-hydroxylase deficiency) [22]

Pregnanolone

Up to 17 ng/mL in women [33]

0.90%

Low

Allopregnanolone

Up to 29 ng/mL in women [33]

0.82%

Low

Medroxyprogesterone

Up to 100 ng/mL following dosing in women [46]

0.67%

Possible significant contribution for individuals with progesterone concentrations on the lower end of reference interval

Corticosterone

• 0.18 – 2.0 ng/mL (18 years and younger) [24]

0.54%

Low

• 0.53 – 1.6 ng/mL (<18 years) [24]

11-Deoxycortisol

• 0.17 – 1.8 ng/mL (pediatric controls) [22]

0.39%

Low, except in patients following metyrapone challenge or who have 11β-hydroxylase deficiency

• Up to 63 ng/mL (11β-hydroxylase deficiency) [22]

• Up to 250 ng/mL (metyrapone challenge) [25]

Nandrolone

Up to 5.16 ng/mL in men following intramuscular injection [47]

0.17%

Low

Pregnenolone

Up to 3.27 ng/mL in women [33]

0.12%

Low

Exemestane

Up to 441 ng/mL in post-menopausal women [48]

0.09%

Possible significant effect if progesterone measured near peak of exemestane plasma concentration

Androstenedione

• Up to 0.86 ng/mL before onset of puberty [30]

0.09%

Low

 

• Up to 3.2 ng/mL in 21-hydroxylase deficiency [30]

 Â